X

Trial Profile

A Double-Blind, Phase III Study to Evaluate the Efficacy, Safety and PK of MRA in Patients With sJIA

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 12 Jul 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tocilizumab (Primary)
Indications Juvenile rheumatoid arthritis
Focus Therapeutic Use
Sponsors Chugai Pharmaceutical

Most Recent Events

03 Jun 2023 Results assessing long-term prognosis of patients participating in phases II (Study MRA011JP), III (Study MRA316JP), and III/IV (Study MRA324JP) presented at the 24th Annual Congress of the European League Against Rheumatism.
01 May 2014 Results published in The Journal of Rheumatology.
22 Mar 2008 Primary efficacy results published in The Lancet March 22 2008

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com